Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Non-Current Liabilities: 2010-2025

Historic Other Non-Current Liabilities for Catalyst Pharmaceuticals (CPRX) over the last 9 years, with Sep 2025 value amounting to $161,000.

  • Catalyst Pharmaceuticals' Other Non-Current Liabilities fell 94.22% to $161,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $161,000, marking a year-over-year decrease of 94.22%. This contributed to the annual value of $315,000 for FY2024, which is 89.44% down from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $161,000 for Q3 2025, which was down 47.90% from $309,000 recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Other Non-Current Liabilities peaked at $14.7 million during Q3 2022, and registered a low of $161,000 during Q3 2025.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $2.6 million (2024), whereas its average is $3.8 million.
  • Data for Catalyst Pharmaceuticals' Other Non-Current Liabilities shows a maximum YoY crashed of 94.22% (in 2025) over the last 5 years.
  • Over the past 4 years, Catalyst Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $14.1 million in 2022, then tumbled by 78.80% to $3.0 million in 2023, then slumped by 89.44% to $315,000 in 2024, then tumbled by 94.22% to $161,000 in 2025.
  • Its Other Non-Current Liabilities stands at $161,000 for Q3 2025, versus $309,000 for Q2 2025 and $259,000 for Q1 2025.